| Primary Hyperaldosteronism |
| Adrenal (Conn's) adenoma | Autonomous aldosterone excess | 40 |
| Bilateral (micronodular) adrenal hyperplasia | Autonomous aldosterone excess | 60 |
| Glucocorticoid-remediable hyperaldosteronism (dexamethasone-suppressible hyperaldosteronism) | Crossover between the CYP11B1 and CYP11B2 genes results in ACTH-driven aldosterone production | <1 |
| Other Causes (Rare) | <1 |
| Syndrome of apparent mineralocorticoid excess (AME) | Mutations in HSD11B2 result in lack of renal activation of cortisol to cortisone, leading to excess activation of the MR by cortisol | |
| Cushing's syndrome | Cortisol excess overcomes the capacity of HSD11B2 to inactivate cortisol to cortisone, consequently flooding the MR | |
| Glucocorticoid resistance | Upregulation of cortisol production due to GR mutations results in flooding of the MR by cortisol | |
| Adrenocortical carcinoma | Autonomous aldosterone and/or DOC excess | |
| Congenital adrenal hyperplasia | Accumulation of DOC due to mutations in CYP11B1 orCYP17A1 | |
| Progesterone-induced hypertension | Progesterone acts as an abnormal ligand due to mutations in the MR gene | |
| Liddle's syndrome | Mutant ENaC beta or gamma subunits resulting in reduced degradation of ENaC keeping the membrane channel in open conformation for longer, enhancing mineralocorticoid action |
No comments:
Post a Comment